top of page

Extended Spectrum Beta-Lactamases (ESBL) & Antibiotics - #MEDSHED

Updated: Jun 11

Welcome to the #MEDSHED! Needing a brief, concise review of clinical pharmacotherapy and disease management? Direct links of reference to content discussed? Look no further than the #MEDSHED series based on infographics and carousel presentations!


🤢 Extended-Spectrum Beta-Lactamases (ESBL) & Antibiotics - #MEDSHED

Extended-spectrum beta-lactamase organisms hydrolyze penicillins, cephalosporins, and aztreonam. Bacteria with ESBL are defined by resistance to expanded-spectrum cephalosporins.

Gram negative rods have continued to mutate into an expansive list of beta-lactamase strains. The Ambler Classification divides them into groups, which I’ve listed above. Groups B-D are expanded resistance mechanisms of ESBL within Group A.

We know ESBL means non-beta lactams antibiotics can be considered. Carbapenems are preferred for invasive ESBL infections due to better outcomes compared to other agents. Carbapenems include ertapenem, meropenem, doripenem, and imipenem. Ertapenem does not cover Acinetobacter, Pseudomonas/Providencia, and Enteroccocus.

Tigecycline, considered a glyclcycline, is also used for ESBL-producing Enterbactericae. SMX-TMP and fluoroquinolones . Nitrofurantoin and fosfomycin are also available oral but limited to use for UTIs

🔍 Website:

Social Links:

Streaming Platforms:

Paypal Donation:


Not medical advice. Educational purposes only. No relationships to report.

Recent Posts

See All


bottom of page